Skip to main content

Table 3 Meta-analysis of the clinical characteristics of the study subjects

From: Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

 

Pooled effect size

(95% CI)

Heterogeneity

Tau squared

# of studies

  

Q value

P value

I Squared

  

Mean age (Years)

50.3 (47.7–52.9)

2872.2

< .001

98.50

72.58

44

Male

53.0 (50.2–55.7) %

180.71

< .001

77.31

8.97

42

Clinical features

 Headache

12.1 (9.1–15.8) %

989.99

< .001

96.26

0.824

38

 Myalgia

22.2 (17.2–28.1) %

621.55

< .001

94.85

0.740

33

 Taste impairment

19.6 (3.8–60.1) %

431.04

< .001

99.30

3.405

4

 Smell impairment

18.3 (1.54–76.2) %

853.88

< .001

99.64

7.254

4

 Dizziness

11.3 (8.5–15.0) %

27.85

.001

67.68

0.156

10

 Features of encephalopathy or cognitive dysfunction

9.4 (2.8–26.6) %

133.92

< .001

95.51

2.70

7

 Ataxia or abnormal gait

2.1 (0.2–23.7) %

6.59

.010

84.83

3.18

2

 Fever

80.6 (74.9–85.3) %

1604.55

< .001

97.44

1.05

42

 Cough

64.1 (59.9–68.0) %

575.30

< .001

93.04

0.26

41

 Neurological complications a

3.0 (0.9–9.6) %

50.01

< .001

92.00

1.66

5

 Acute CVD

2.5 (1.0–6.1) %

15.3

0.004

74.41

0.72

5

Laboratory findings

 Serum CK (U/L)

85.5 (73.8–97.3)

369.93

< .001

96.21

434.78

15

 Serum LDH (U/L)

263.4 (234.6–292.3)

648.50

< .001

97.84

3026.56

15

 Lymphocyte (a10^9/L)

1.08 (1.02–1.14)

549.37

< .001

95.08

0.024

28

 Neutrophils (a10^9/L)

3.44 (3.21–3.68)

214.45

< .001

90.67

0.244

21

 Monocytes (a10^9/L)

0.39 (0.37–0.42)

42.66

< .001

78.90

0.001

10

 Severe COVID-19

31.1 (21.9–42.2) %

739.23

< .001

97.02

1.16

23

 ICU admission

20.6 (14.1–29.0) %

231.12

< .001

91.34

0.81

21

Comorbidities

 Any previous comorbidity

37.4 (33.1–41.9) %

274.90

< .001

89.08

0.231

31

 Diabetes Mellitus

10.3 (8.3–12.8) %

265.15

< .001

88.68

0.360

31

 Hypertension

20.4 (17.0–24.2) %

196.73

< .001

87.292

0.253

26

 Heart diseases

9.7 (7.2–12.9) %

426.59

< .001

93.201

0.706

30

 Neurological diseases

5.7 (3.3–9.7) %

175.60

< .001

90.319

1.213

18

 Malignancy

2.7 (2.0–3.6) %

61.429

< .001

59.303

0.319

26

 Pulmonary diseases

3.4 (2.2–5.0) %

260.24

< .001

89.240

0.973

29

 Chronic kidney disease

2.3 (1.3–3.9) %

75.189

< .001

81.380

0.858

15

 Chronic liver disease

3.5 (2.6–4.7) %

32.726

.005

54.165

0.187

16

 Smoking

9.2 (6.4–13.0) %

146.643

< .001

89.771

0.501

16

  1. aNeurological complications include: Cerebrovascular diseases (ischemic stroke, cerebral hemorrhage, and venous sinus thrombosis), rhabdomyolysis, and seizures
  2. P < .05 indicates the presence of heterogeneity